Abstract
蔡思宇,夏舜英,谢海宝,姚雪艳,王利宏.180例高胆固醇血症患者调脂治疗现状调查[J].Chinese journal of Epidemiology,2002,23(5):378-382
180例高胆固醇血症患者调脂治疗现状调查
A survey on the status of lipid-lowering therapy in 180 hypercholesterolemic patients
Received:January 29, 2002  
DOI:
KeyWord: 血脂  高胆固醇血症  抗胆固醇血症药  治疗达标
English Key Word: Lipid profile  Hypercholesterolemia  Anticholesteremic agents  Treatment to target
FundProject:
Author NameAffiliation
CAI Siyu Department of Cardiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China 
XIA Shunying Department of Cardiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China 
XIE Haibao 浙江省老年医学研究所 
YAO Xueyan 浙江大学医学院附属第一医院心内科 
WANG Lihong 浙江大学医学院附属第一医院心内科 
Hits: 3714
Download times: 1147
Abstract:
      目的了解高胆固醇血症患者经调脂治疗后,达到国内《血脂异常防治建议》要求的总胆固醇与低密度脂蛋白胆固醇治疗目标的比例。方法选择已接受同一调脂药物治疗至少2个月的高胆固醇血症患者,测定其血脂水平,判断是否达到治疗目标。同时记录患者的心血管病危险因子以及调脂治疗的药物名称。结果共入选180例患者,平均年龄65.8岁。其中6.7%的患者无危险因子也无明确的动脉粥样硬化疾病(低危组),65.5%的患者有危险因子但无明确的动脉粥样硬化疾病(高危组),27.8%的患者有明确的动脉粥样硬化疾病或糖尿病。在整个人群中,仅有44%患者的总胆固醇与低密度脂蛋白胆固醇水平同时达到治疗目标。低危组与高危组患者的达标率高于动脉粥样硬化疾病与糖尿病组。对4种不同调脂药物与达标率的关系也进行了研究:辛伐他汀组为51.8%,普伐他汀组为42.9%,氟伐他汀组为31.6%,其他药物组为12.5%。结论超过一半正在接受调脂治疗的患者,其总胆固醇与低密度脂蛋白胆固醇水平并未达到治疗目标。调查表明在《血脂异常防治建议》与临床实践之间仍然存在一定差距,提示需要更积极的调脂治疗。
English Abstract:
      Objective To determine the percentage of hypercholesterolemic patients who had met the criteria as total cholesterol (TC) and low density lipoprotein cholesterol (LDL C), defined by the Chinese National Recommendations for Prevention and Treatment of Dyslipidemia. Methods Adult patients with hypercholesterolemia, who had been receiving the same lipid lowering therapy for at least 2 months, were enrolled. Lipid levels were determined at the time of enrollment, to assess whether the patients' lipid levels had reached the criteria for treatment. Patients' cardiovascular risk factors and lipid lowering treatments were also collected. Results One hundred and eighty patients with mean age of 65.8 were studied. Of these, 6.7 % had no risk factors and no definite disease of atherosclerosis (low risk group), 65.5 % had risk factors but no documented atherosclerosis (high risk group), and 27.8 % had established atherosclerosis diseases or diabetes mellitus. Overall, only 44% of patients achieved both TC and LDL C target levels. The success rates were higher among low and high risk groups than that among patients with atherosclerosis or diabetes mellitus. The relationship between four different lipid lowering drug therapies and successful patient outcome was also investigated. The success rates were 51.8 % for simvastatin, 42.9 % for pravastatin, 31.6 % for fluvastatin, 12.5 % for other drugs respectively. Conclusion More than half of the hypercholesterolemic patients receiving lipid lowering therapy had not achieved TC and LDL C target levels. Data from this study indicated that a significant gap still existed between dyslipidemia prevention principles and clinical practices, suggesting that more aggressive treatment of dyslipidemia is needed
View Fulltext   Html FullText     View/Add Comment  Download reader
Close